LPCN vs. QNCX, IBIO, VHAQ, IKNA, CNTX, XFOR, KPTI, CLSD, MRSN, and MURA
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Quince Therapeutics (QNCX), iBio (IBIO), Viveon Health Acquisition (VHAQ), Ikena Oncology (IKNA), Context Therapeutics (CNTX), X4 Pharmaceuticals (XFOR), Karyopharm Therapeutics (KPTI), Clearside Biomedical (CLSD), Mersana Therapeutics (MRSN), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry.
Lipocine vs.
Quince Therapeutics (NASDAQ:QNCX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
Quince Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.
Lipocine received 340 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 67.91% of users gave Lipocine an outperform vote.
Lipocine has higher revenue and earnings than Quince Therapeutics. Lipocine is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.
30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by company insiders. Comparatively, 6.1% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Lipocine's return on equity of -19.17% beat Quince Therapeutics' return on equity.
Quince Therapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 529.14%. Lipocine has a consensus price target of $10.00, suggesting a potential upside of 190.70%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Quince Therapeutics is more favorable than Lipocine.
In the previous week, Quince Therapeutics and Quince Therapeutics both had 1 articles in the media. Quince Therapeutics' average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score.
Summary
Quince Therapeutics beats Lipocine on 8 of the 15 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
This page (NASDAQ:LPCN) was last updated on 3/10/2025 by MarketBeat.com Staff
Free LPCN Stock Alerts